Business Field

Worldwide demand is increasing for effective drugs to overcome new and intractable diseases. Toyama is working toward this goal by concentrating its R&D in three fields: anti-infective agents, CNS and cardiovascular agents, and anti-inflammatory agents. To speedily bring new pharmaceuticals to the world market, Toyama has created subsidiaries in the U.S. and U.K. as bases for clinical research.

Our core strength is the development of new pharmaceuticals. This is evidenced by our numerous technology exports and our royalty income, which is the highest among mid-sized Japanese pharmaceutical companies.

Pharmaceuticals now in the pipeline include T-705, an antiviral agent; T-5224, an oral antirheumatic agent; and T-817MA, a treatment for Alzheimer's disease. We have formed strategic partnerships with domestic and overseas pharmaceutical manufacturers to deliver these products quickly and efficiently to medical institutions around the world.

To promote the proper use of pharmaceuticals, we have established a Quality Assurance Center to secure world-class quality, and enacted a comprehensive environmental management policy.

Toyama is taking an aggressive, outward-looking approach, globalizing its activities with the aim of becoming a key pharmaceutical manufacturer.